thesis about lung cancer

Lung Cancer Research Results and Study Updates

See Advances in Lung Cancer Research for an overview of recent findings and progress, plus ongoing projects supported by NCI.

For certain people with early-stage non-small cell lung cancer, sublobar surgery to remove only a piece of the affected lung lobe is as effective as surgery to remove the whole lobe, new research shows.

Pragmatica-Lung is a phase 3 clinical trial for people with non-small cell lung cancer that has spread beyond the lungs (stage 4 cancer). Researchers seek to confirm if the combination of pembrolizumab and ramucirumab helps people with lung cancer live longer than if they were on standard chemotherapy. This trial is part of a broader effort by NCI and FDA to modernize clinical trials.

On August 11, the Food and Drug Administration (FDA) gave accelerated approval to trastuzumab deruxtecan (Enhertu) for adults with non-small cell lung cancer (NSCLC) that has a specific mutation in the HER2 gene. Around 3% of people with NSCLC have this kind of HER2 mutation.

Giving people with early-stage lung cancer the immunotherapy drug nivolumab (Opdivo) and chemotherapy before surgery can substantially delay the progression or return of their cancer, a large clinical trial found.

Atezolizumab (Tecentriq) is now the first immunotherapy approved by FDA for use as an additional, or adjuvant, treatment for some patients with non-small cell lung cancer. The approval was based on results of a clinical trial called IMpower010.

Quitting smoking after a diagnosis of early-stage lung cancer may help people live longer, a new study finds. The study, which included more than 500 patients, also found that quitting smoking delayed the cancer from returning or getting worse.

NCI scientists and their international collaborators have found that the majority of lung cancers in never smokers arise when mutations caused by natural processes in the body accumulate. They also identified three subtypes of lung cancer these individuals.

FDA has approved the first KRAS-blocking drug, sotorasib (Lumakras). The approval, which covers the use of sotorasib to treat some patients with advanced lung cancer, sets the stage for other KRAS inhibitors already in development, researchers said.

Combining the chemotherapy drug topotecan and the investigational drug berzosertib shrank tumors in some patients with small cell lung cancer, results from an NCI-supported phase 1 clinical trial show. Two phase 2 trials of the combination are planned.

Mortality rates from the most common lung cancer, non-small cell lung cancer (NSCLC), have fallen sharply in the United States in recent years, due primarily to recent advances in treatment, an NCI study shows.

In a study of more than 50,000 veterans with lung cancer, those with mental illness who received mental health treatment—including for substance use—lived substantially longer than those who didn’t participate in such programs.

FDA has granted accelerated approval for selpercatinib (Retevmo) to treat certain patients with thyroid cancer or non-small cell lung cancer whose tumors have RET gene alterations. The drug, which works by blocking the activity of RET proteins, was approved based on the results of the LIBRETTO-001 trial.

Osimertinib (Tagrisso) improves survival in people with non-small cell lung cancer with EGFR mutations, updated clinical trial results show. People treated with osimertinib lived longer than those treated with earlier-generation EGFR-targeted drugs.

A large clinical trial showed that adding the immunotherapy drug durvalumab (Imfinzi) to standard chemotherapy can prolong survival in some people with previously untreated advanced small cell lung cancer.

The investigational drug selpercatinib may benefit patients with lung cancer whose tumors have alterations in the RET gene, including fusions with other genes, according to results from a small clinical trial.

FDA has approved entrectinib (Rozlytrek) for the treatment of children and adults with tumors bearing an NTRK gene fusion. The approval also covers adults with non-small cell lung cancer harboring a ROS1 gene fusion.

Clinical recommendations on who should be screened for lung cancer may need to be reviewed when it comes to African Americans who smoke, findings from a new study suggest.

Use of a multipronged approach within hospitals, including community centers, not only eliminated treatment disparities among black and white patients with early-stage lung cancer, it also improved treatment rates for all patients, results from a new study show.

In everyday medical care, there may be more complications from invasive diagnostic procedures performed after lung cancer screening than has been reported in large studies.

The Lung Cancer Master Protocol, or Lung-MAP, is a precision medicine research study for people with advanced non-small cell lung cancer that has continued to grow after treatment. Patients are assigned to different study drug combinations based on the results of genomic profiling of their tumors.

On December 6, 2018, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with a standard three-drug regimen as an initial treatment for advanced lung cancer that does not have EGFR or ALK mutations.

A new study has identified a potential biomarker of early-stage non–small cell lung cancer (NSCLC). The biomarker, the study’s leaders said, could help diagnose precancerous lung growths and early-stage lung cancers noninvasively and distinguish them from noncancerous growths.

Results from two large clinical trials should cement the value of the drugs brigatinib (Alunbrig) and durvalumab (Imfinzi) in treating non-small cell lung cancer (NSCLC). The trial results, several experts said, confirm that the drugs can improve the outcomes of patients with advanced NSCLC.

Cancer researchers have trained a computer program to scan images of tissue samples to differentiate normal lung tissue from the two most common forms of lung cancer. The program also learned to detect cancer-related genetic mutations in the samples.

In a large clinical trial, the immunotherapy drug atezolizumab (Tecentriq), combined with a standard chemotherapy regimen, modestly increased survival in patients with advanced small cell lung cancer (SCLC). The trial is the first in more than 20 years to show a survival improvement in this cancer.

Results from a large clinical trial show combining an immune checkpoint inhibitor with chemotherapy helped some patients with advanced lung cancer live longer than chemotherapy alone. How will this change the lung cancer treatment landscape?

An analysis of data from a demonstration project led by the Veterans Health Administration may help to better define who is most likely to benefit from lung cancer screening.

Patterns of gene expression may be different in the tumors of some African Americans than in those of whites, a new study has found, and these biological differences may contribute to racial disparities in lung cancer.

FDA has approved alectinib (Alecensa) as a first-line treatment option for patients with advanced non-small cell lung cancer that is ALK positive. Alectinib is the third ALK inhibitor to be approved in this setting.

A collection of material about the ALCHEMIST lung cancer trials that will examine tumor tissue from patients with certain types of early-stage, completely resected non-small cell lung cancer for gene mutations in the EGFR and ALK genes, and assign patients with these gene mutations to treatment trials testing post-surgical use of drugs targeted against these mutations.

FDA approved the combination of dabrafenib (Tafinlar®) and trametinib (Mekinist®) for the treatment of metastatic non-small cell lung cancer (NSCLC) that has an alteration in the BRAF gene called the V600E mutation.

The FDA has approved the targeted therapy ceritinib as an initial treatment for patients with lung cancer that has a mutation in the ALK gene.

FDA approved the immune checkpoint inhibitor pembrolizumab to be used with chemotherapy as a first-line treatment for non-small cell lung cancer.

On April 28, the FDA granted accelerated approval to the targeted therapy brigatinib (Alunbrig™) for patients with metastatic non-small cell lung cancer (NSCLC) and alterations in the ALK gene whose cancer has progressed during their initial therapy.

A demonstration project by the Veterans Health Administration is highlighting some of the complexities and challenges associated with the expansion of lung cancer screening in the United States.

Results from a phase III trial showed that the immune checkpoint inhibitor pembrolizumab (Keytruda®) improved progression-free and overall survival among patients with advanced non-small cell lung cancer compared with chemotherapy.

The FDA has approved atezolizumab and expanded the approval of pembrolizumab for some patients with non-small cell lung cancer.

A new study has identified a potentially critical vulnerability in lung cancers that have mutations in the KRAS gene, and showed that a drug already under study may be able to exploit it.

A blog post on a modeling study from NCI researchers suggesting that individualized, risk-based selection of ever-smokers for lung cancer screening may prevent more lung cancer deaths compared with current screening recommendations.

The FDA has approved uses of the targeted therapy crizotinib (Xalkori®) for patients with advanced lung cancer whose tumors have alterations in the ROS1 gene.

The FDA has approved alectinib to treat patients with metastatic ALK-positive non-small cell lung cancer who have stopped responding to or who are unable to tolerate crizotinib.

The FDA has approved two targeted therapies, osimertinib (Tagrisso™) and necitumumab (Portrazza™), for the treatment of some patients with advanced lung cancer.

Patients with lung cancer are benefiting from the boom in targeted and immune-based therapies. With a series of precision medicine trials, NCI is keeping pace with the rapidly changing treatment landscape for lung cancer.

The FDA has approved the drug pembrolizumab to treat patients with advanced non-small cell lung cancer (NSCLC) whose tumors express a protein called PD-L1.

Lung Cancer Essay

Treatment Of Lung Cancer

Lung Cancer Lung cancer is the most common cancer in the world in recent decades. An estimated 1.8 million new cases were reported in 2012 (12.9% of the total), with 58% in less developed regions (WHO, 2017). Lung cancer is the leading cause of cancer death and the second most commonly diagnosed cancer among men and women in the United States. Most patients are diagnosed at an advanced stage, resulting in a very low survival rate at 5 years (ASCO, 2015). In 2011, 14% of all cancer diagnoses and 27%

Speech On Lung Cancer

Lung Cancer: Awareness & Prevention Lung cancer is the leading cause of cancer deaths among men and women in the Bangladesh, according to the Bangladesh Lung Foundation. The treatment of this disease is not up to the mark in Bangladesh. Lack of good facilities, skilled manpower and physical infrastructure, ineffective and inefficient treatment, corruption in the health management, politics among the health service providers, disparity in production of drugs etc are the reasons why our country is

Lung Cancers And Its Effects

INTRODUCTION What are lung cancers? Lung cancers are the abnormal cells which grow in uncontrolled manner in one or both lungs. They do not function as normal lung cells and do not develop into healthy lung tissue. The abnormal cells can grow, form tumours and interfere with the normal functions of the lung (Lungcancer.org, 2015). Lung cancers can be divided into two major types, namely non-small cell lung cancers (NSCLC) and small cell lung cancers (SCLC). NSCLC can be further classified into three

Lung Cancer : The Risks Of Lung Cancer And Cancer

Lung Carcinoma commonly known as lung cancer is a kind of cancer that starts in the lungs. The people with the highest risk of getting lung cancer is the people who smoke. Smoking is increases the patient’s risk of getting lung cancer with the length of time the patient smokes and the number of cigarettes the patient smoked. However, if the patient quits smoking, even after smoking for many years, the patient can significantly reduce their chances of developing lung cancer. (Mayo Clinic Staff, 2015)

Lung Cancer

Lung cancer is the most commonly diagnosed cancer in the world, according to the World Health Organisation. In the UK, it 's the second most-frequently occurring cancer among men (after prostate cancer), accounting for 1 in 7 new cases, and the third most-frequently diagnosed cancer in women (after breast and bowel cancer) accounting for about 1 in 9 new cases. However, numbers have dropped considerably in recent times, by about 16% in the last decade alone. Dr Patrisha Macnair last medically reviewed

LUNG CANCER Mohamed Almasmary Bio240 Anatomy Physiology 1 4/13/14 Lung cancer is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Lung cancer originates when normal lung cells become cancer cells, usually after a series of mutations, and begin to divide out of control. Lung Cancer is a disease which consists of uncontrolled cell growth in lung tissues. Lung cancer consists of two types, Non-small cell lung cancer, and small cell lung cancer. (NSCLC)

School Lung Cancer Lung cancer is “the uncontrolled growth of abnormal cells in one or both lungs”. These abnormal cells do not carry out the functions of normal lung cells and do not develop into healthy lung tissue. As they grow, “the abnormal cells can form tumors and interfere with the functioning of the lung, which provides oxygen to the body via the blood”. There are two major types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Staging lung cancer is based

Lung Cancer : Cancer And Cancer

Lung cancer is the number one leading cause of cancer deaths in the United States. Lung cancer kills more people than any other cancer, such as; breast cancer, colon, prostate, or ovarian. There are two types of lung cancer, small cell lung cancer and non-small lung cancers. These two lung cancers grow and spread differently. Small cell lung cancer tends to spread quickly and makes up about 10-15 percent of the lung cancers. Non-small lung cancer is the most common type, it attributes to about

The Genetics of Lung Cancer Catherine Hayworth BIO 355A/357A June 14, 2012 Colorado Christian University Cancer can be one of the hardest battles that one must face, whether that battle is lost or won, it changes the lives of everyone involved. Lung cancer is one of the most diagnosed cancers and it affects the lining of the lungs and the ability to breathe. Lung cancer is the number one killer of men and women than any other cancer worldwide. This cancer is mostly found in smokers and

Lung Cancer Lung cancer is one of the most common cancers in the world, its deadly claws stretched over all continents in the world. However, lung cancer is not just a disease; it can act as a magnifying glass; many social problems and goodness of society can be revealed through the causes of lung cancer. Lung cancer is formed when the cells of the lungs grow in an uncontrolled way, this creates a lump or a tumor which can either be malignant or benign. Smoking and unhealthy diets are all causes

Health Care For Lung Cancer

2012 there was in increase in lung cancer deaths by 3.5%, this percent is still rising in women while it’s stable in men (CDC, 2014). Nowadays, about 402,324 Americans have lung cancer. In 2014, the newly diagnosed lung cancer cases are 224,210, they represent 13% of all cancer diagnosis (ACS, 2014). Lung cancer affects old people and always they diagnosed in the last five years of their life. Around 80% of people who live with lung cancer their ages more than 60 years (USNIH, 2011). In Kentucky

Essay about Lung Cancer

Cancer of the lung was nearly nonexistent in the early 1900’s. By the middle of the 20th century an epidemic became apparent throughout the United States and the rest of the world. It is primarily correlated with the widespread abundance of cigarette smoking in the world. The tobacco industry has multiplied its production immediately prior to World War I. There was a typical 20 to 30 year lagging period between the initiation of cigarette smoking and the actual tumor formation in the lungs. Lung

Cause And Effect Of Lung Cancer

In addition, since emphysema is said to be one of the causes of lung cancer, it can be said that smoking is also related to lung cancer. As is well known, currently, there are no effective treatment for cancer. Smoking habit is the main cause of lung cancer. The probability of a smoker becoming lung cancer is said to be about ten times more than that of a non-smoker. Also, smoking hurts their own DNA, that is, the risk of lung cancer extends to offspring. There may be people who think smoking cessation

Lung Cancer. Lung Cancer Is An Uncontrolled Growth Of Abnormal

Lung Cancer Lung cancer is an uncontrolled growth of abnormal cells that start off in one or both lungs they usually in the cells that line the air passages (medianews). The cells from the abnormal can’t develop into a healthy lung tissue and spread quickly and form tumors. Lung cancer has been held responsible on many factors but the greatest one is smoking. Smoking is the main cause of lung cancer. A person can get clung cancer by the way they smoke, the more and longer they smoke the changes

Breast Cancer And Lung Cancer

Cancer has been taking the lives of many for years now. Even though cancer has affected people for centuries, we have yet to find a cure for the disease, but we are now able to identify the different forms of cancer such as breast cancer and lung cancer. With scientific innovations, the medical field has been able to make advances in treatments. With all the new advancements, it is clear how much new information has been exposed. Exposing such information permits the public to become more knowledgeable

• 2 Works Cited

Brief Description: Lung cancer, as with all cancers, is an uncontrollable increase of cells. It happens within the lung tissue, but it could also go on to affect other nearby tissue and spread to further out than just the lungs. Cellular / Molecular Basis: Lung cancer has two types; small cell and non small cell. The two types can be identified by their appearance when looked at with a microscope. It usually affects the cells that are lined along air passages in the lungs. Causes: The foremost

Papers On Lung Cancer

Lung cancer is the growth of abnormal cells in one or both of the lungs. This is usually in the cells that line the air passages. The abnormal cells that do not develop into healthy lung tissues divide rapidly to form tumors. Lungs are the spongy organs in the chest that take in oxygen and release carbon dioxide when breathing. They are essential to live, so lung cancer can be very dangerous. This disease is quite common, making it important to know at least a little bit about. Lung cancer

Lung Cancer Epidemiology

Anatomy There are five lobes in the lung, three on the right and two on the left. Each lobe is divided by five segments, each supplied by tertiary bronchi, except for the right upper and right middle lobes, which are divided into three and two segments, respectively. Lymph nodes draining the lung are divided into intrapulmonary, hilar, and mediastinal nodal groups along the secondary bronchi, main bronchi, and surrounding tracheal and vascular structures within the mediastinum, respectively . Epidemiology

Lung Cancer Research

Lung cancer is the second most common cancer and leading cause of cancer death among both men and women, according to the American Cancer Society. Prostate cancer is more common in men, while breast cancer is more common in women. The ACS estimates in United States for 2014, approximately 224,210 new cases of lung cancer and 159,260 deaths from lung cancer. When we learn someone is diagnosed with lung cancer, the first question that comes to mind, “Did they smoke?”. We all identify the major cause

Lung cancer is the number one cause of death by cancer. It has affected my family tremendously. My grandma was diagnosed with stage four lung cancer in June of 2014, it has been almost two years and she is still fighting. She has gone through so much and it really takes a toll on your body. She has gone through years of chemotherapy, radiation, so many drugs and recently was put on oxygen that she needs 24/7. I pray every day that people will stop smoking and not take the risk of developing lung

Popular Topics

• Lying Essay
• Lyndon Essay
• Lyrical Ballads Essay
• Lysistrata Essay
• M Butterfly Essay
• M.C. Escher Essay
• Mac vs. PC Essay
• Macbeth Essay
• Macbeth Ambition Essay
• Macbeth Blood Essay

Do a more advanced search »

Search for dissertations about: "lung cancer"

Showing result 1 - 5 of 324 swedish dissertations containing the words lung cancer .

1. Lung Cancer : Epidemiological and Clinical Studies with Special Reference to Surgical Treatment

Author : Gunnar Myrdal ; Elisabeth Ståhle ; Mats Lambe ; Bengt Bergman ; Uppsala universitet ; [] Keywords : MEDICAL AND HEALTH SCIENCES ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICAL AND HEALTH SCIENCES ; Surgery ; lung cancer ; surgical treatment ; early mortality ; survival ; smoking ; quality of life ; adenocarcinoma ; incidence ; Sweden ; Kirurgi ; Surgery ; Kirurgi ; Thoracic and Cardivascular Suregery ; kirurgi ; särskilt thoraxkirurgi ;

Abstract : From being a rare disease in the early 1900s, lung cancer is today the most common forms of cancer worldwide. This development is due to the gradual uptake of cigarette smoking in different populations and birth cohorts during the past 75 years. READ MORE

2. Lung cancer in males : an epidemiological study in northern Sweden with special regard to smoking and occupation

Author : Lena Damber ; Umeå universitet ; [] Keywords : MEDICAL AND HEALTH SCIENCES ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICAL AND HEALTH SCIENCES ; case-control study ; epidemiology ; lung cancer ; occupational risk ; factors ; smoking ; radon ; cell types ; validity ;

Abstract : In a case-control study comprising 589 cases of male lung cancer in northern Sweden longitudinal data concerning occupations, employments and smoking habits were collected by questionnaires.Pipe smoking was as common as cigarette smoking and gave very similar relative risk. READ MORE

3. LRIG1 in lung cancer : prognostic effects and mechanistic studies

Author : Samuel Kvarnbrink ; Mikael Johansson ; Håkan Hedman ; Odd Terje Brustugun ; Umeå universitet ; [] Keywords : MEDICAL AND HEALTH SCIENCES ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICAL AND HEALTH SCIENCES ; lung cancer ; metastasis ; prognosis ; LRIG1 ; LRIG3 ; LMO7 ; LIMCH1 ; Oncology ; onkologi ;

Abstract : Lung cancer is the leading cause of cancer-related death worldwide as well as in Sweden. Non-small cell lung cancer (NSCLC) is the predominant form, which is largely subdivided into adenocarcinomas and squamous cell carcinomas. READ MORE

4. Cancer and Inflammation : Role of Macrophages and Monocytes

Author : Alexander Hedbrant ; Jonny Wijkander ; Dick Delbro ; Ann Erlandsson ; Anita Sjölander ; Karlstads universitet ; [] Keywords : NATURAL SCIENCES ; NATURVETENSKAP ; MEDICAL AND HEALTH SCIENCES ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICAL AND HEALTH SCIENCES ; MEDICIN OCH HÄLSOVETENSKAP ; NATURVETENSKAP ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICIN OCH HÄLSOVETENSKAP ; NATURAL SCIENCES ; MEDICAL AND HEALTH SCIENCES ; MEDICAL AND HEALTH SCIENCES ; M1 macrophages ; M2 macrophages ; colon cancer ; lung cancer ; prostaglandin E2 ; Biomedical Sciences ; Biomedicinsk vetenskap ;

Abstract : Macrophages are cells of the innate immune system that can be found in large quantities in cancer tumors and affect cancer progression by regulating growth and invasiveness of cancer cells. There are two main phenotypes of macrophages denoted M1 and M2. READ MORE

5. Body Protein and its Change in Patients During Anti-Tumor Treatment

Author : Lianna Kadar ; Malmö Institutionen för kliniska vetenskaper ; [] Keywords : MEDICIN OCH HÄLSOVETENSKAP ; MEDICAL AND HEALTH SCIENCES ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICAL AND HEALTH SCIENCES ; Cytology ; Gastrointestinal tumors ; Breast cancer ; Lung cancer ; Prognosis ; Body protein ; oncology ; cancerology ; Cytologi ; onkologi ; cancer ;

Abstract : The purpose of this study was to investigate how total body protein and its fraction of body weight (body protein fraction) change in cancer patients during different anti-tumor treatments, and to see if these changes have any clinical significance in the form of prognostic value or correlation with disease course and tumor response. In 84 patients, 28 with lung cancer, 24 with gastrointestinal tumors, 30 with breast cancer, 1 with non-Hodgkin lymphoma and 1 with kidney cancer, the total amount of body nitrogen was measured using an in vivo prompt gamma neutron activation technique. READ MORE

Searchphrases right now

• SYSTEM FOR DIESEL ENGINE
• Geovetenskap och miljövetenskap Geologi
• Lena Nilsson
• Reference Attribute Grammars
• National Drug Policy Programme
• Principal component analysis PCA
• target therapy
• model complexity
• Pragmatic competence
• client processing
• FLEXIBILITY

Popular searches

• optimal power flow
• traumatic brain injury
• urinary tract infection by e.coli and virulence
• bragg grating
• Online participation
• gene structure
• Health Economics theory
• Gene Expression
• Molecular Cellbiology
• Phd dissertations

Popular dissertations yesterday (2023-03-11)

• Noise in the preschool : health and preventive measures
• Determinants and clinical implications of circulating fatty acids in individuals with chronic kidney disease
• Compact sprawl : Exploring public open space and contradictions in urban density
• Risk management in construction projects : a comparative study of the different procurement options in Sweden
• Inflammatory bowel disease : occurrence, causation and cancer risk
• Children with orofacial clefts : dental caries and health-related quality of life
• Hepatitis B virus RNA in serum and liver tissue - quantification using digital PCR
• Understanding information sharing in supply chains - Identifying contingency factors that impact benefits of information sharing
• Urban air quality and indicators of respiratory problems
• Human interaction as a model for spoken dialogue system behaviour
• Popular complementary terms: essays, phd thesis, master thesis, papers, importance, trend, impact, advantages, disadvantages, role of, example, case study.

See yesterday's most popular searches here . Dissertations.se is the english language version of Avhandlingar.se .